<DOC>
	<DOCNO>NCT01886820</DOCNO>
	<brief_summary>To Determine Efficacy Safety [ 18F ] NAV4694 PET Detection Cerebral Î²-Amyloid When Compared With Postmortem Histopathology</brief_summary>
	<brief_title>A Phase 3 Clinical Trial Evaluate Efficacy Safety 18FNAV4694 PET Detection Cerebral Beta-Amyloid When Compared With Postmortem Histopathology</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Male female subject least 21 year age . Subjects life expectancy approximately 6 month Subject health adequate determine investigator receive [ 18F ] NAV4694 Female subject childbearing potential negative urine pregnancy test day [ 18F ] NAV4694 injection . Must exhibit adequate visual , auditory , communication capability enable compliance study procedure . This include able lie flat MRI CT PET scanner period approximately 1 hour . Subjects must willing donate brain post mortem examination upon death ( consent obtain manner specific country/region involve ) . Subjects fully inform study , include provision Health Insurance Portability Accountability Act ( HIPAA ) , applicable , informed consent assent sign date ( time ) subject and/or subject 's legally acceptable representative ( LAR ) ( individual dementia ) . Scheduled surgery and/or another invasive procedure within time period 7 day [ 18F ] NAV4694 injection . Has severe cerebral macrovascular ( i.e. , multistroke ) disease brain tumor ( metastasis/brain cancer ) verify MRI prohibits sample require prespecified ROIs . Has history transmissible spongiform encephalopathy ( prion disease ) . Has receive contrast material ( Xray , MRI ) radiopharmaceutical within 48 hour prior , therapeutic radiopharmaceutical ( e.g. , 131I ) within 10 day prior , radiopharmaceutical administration within 10 radioactive halflives prior administration investigational product administration substance plan within 7 day investigational product administration . Is allergic investigational product constituent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Terminally Ill</keyword>
</DOC>